retapamulin (altabax) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Retapamulin is a topical antibiotic which was approved by FDA (Altabax brand name) for the treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Retapamulin exerts its antibacterial action by binding to 50S subunit of the bacterial ribosome.   NCATS

Chemistry

  • SMILES: C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2C[C@H]3CC[C@@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
  • InChIKey: STZYTFJPGGDRJD-NHUWBDDWSA-N
  • Mol. Mass: 517.78
  • ALogP: 5.25
  • ChEMBL Molecules:
    retapamulin  
    retapamulin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$14.1580 - $18.4820
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

aitabax | altabax | altargo | mutilin | retapamulin | retpamulin | sb275833 | sb 275833 | sb-275833

Organizations (15)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Impetigo

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Bacterial Infections (Phase 4)

Coinfection (Phase 4)

Dermatitis, Atopic (Phase 4)

Eczema (Phase 4)

Folliculitis (Phase 4)

Impetigo (Phase 4)

Methicillin-Resistant Staphylococcus aureus (Phase 4)

Orthopedic Procedures (Phase 2)

Soft Tissue Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue